Lexicon Pharmaceuticals, Inc.

PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation (2021) Gulluni F, Prever L, Li H, Krafcikova P, Corrado I, Lo WT, Margaria JP, et al. Journal article Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome (2020) Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RR, Bergsland E, Welin S, et al. Journal article Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome (2019) Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, et al. Journal article Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials (2019) Anthony L, Kulke M, Caplin M, Bergsland E, Oberg K, Pavel ME, Horsch D, et al. Conference contribution Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. (2019) Anthony LB, Kulke MH, Caplin ME, Bergsland E, Oberg K, Pavel M, Hoersch D, et al. Journal article Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR (2018) Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, et al. Journal article Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease (2018) Lapuerta P, Kulke MH, Pavel ME, Biran T, Fleming R, Zacks JS, Hoffmanns P, Warner RRP Conference contribution Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial (2018) Pavel ME, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, et al. Journal article